NZ734252A - Blockers of the growth hormone receptor in disease prevention and treatment - Google Patents
Blockers of the growth hormone receptor in disease prevention and treatmentInfo
- Publication number
- NZ734252A NZ734252A NZ734252A NZ73425216A NZ734252A NZ 734252 A NZ734252 A NZ 734252A NZ 734252 A NZ734252 A NZ 734252A NZ 73425216 A NZ73425216 A NZ 73425216A NZ 734252 A NZ734252 A NZ 734252A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- blockers
- growth hormone
- hormone receptor
- disease prevention
- Prior art date
Links
- 102100020948 Growth hormone receptor Human genes 0.000 title abstract 2
- 108010068542 Somatotropin Receptors Proteins 0.000 title 1
- 230000006806 disease prevention Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 206010000599 Acromegaly Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 abstract 1
- 101710132484 Cytokine-inducible SH2-containing protein Proteins 0.000 abstract 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 abstract 1
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 abstract 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 abstract 1
- 102000001712 STAT5 Transcription Factor Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115356P | 2015-02-12 | 2015-02-12 | |
| PCT/US2016/017717 WO2016130901A2 (en) | 2015-02-12 | 2016-02-12 | Blockers of the growth hormone receptor in disease prevention and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ734252A true NZ734252A (en) | 2020-06-26 |
Family
ID=56615057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ734252A NZ734252A (en) | 2015-02-12 | 2016-02-12 | Blockers of the growth hormone receptor in disease prevention and treatment |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10246446B2 (enExample) |
| EP (1) | EP3256465B1 (enExample) |
| JP (2) | JP6930916B2 (enExample) |
| KR (1) | KR20180016333A (enExample) |
| CN (1) | CN107438605B (enExample) |
| AU (1) | AU2016219173B2 (enExample) |
| BR (1) | BR112017017182A2 (enExample) |
| CA (1) | CA2976219C (enExample) |
| ES (1) | ES2871551T3 (enExample) |
| IL (1) | IL253943A0 (enExample) |
| MX (1) | MX383010B (enExample) |
| NZ (1) | NZ734252A (enExample) |
| RU (1) | RU2726254C2 (enExample) |
| WO (1) | WO2016130901A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| CN112153974A (zh) | 2018-03-15 | 2020-12-29 | 南加利福尼亚大学 | 禁食模仿膳食(fmd)而非仅饮水禁食促进炎症和ibd病理学的逆转 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9701010D0 (sv) * | 1997-03-19 | 1997-03-19 | Pharmacia & Upjohn Ab | Antibody |
| JPWO2002096892A1 (ja) | 2001-05-31 | 2004-09-09 | 小野薬品工業株式会社 | オキサジアゾール誘導体化合物およびその化合物を有効成分とする薬剤 |
| WO2006001770A1 (en) * | 2004-06-28 | 2006-01-05 | Biovitrum Ab | Method for identifying modulators of cytokine class i receptor |
| RU2415134C9 (ru) * | 2005-08-15 | 2011-05-27 | Этерна Центарис ГмбХ | Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе |
| US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
| AU2008352540B2 (en) * | 2008-03-14 | 2012-06-28 | Biocon Limited | A monoclonal antibody and a method thereof |
| JP5731501B2 (ja) * | 2009-07-28 | 2015-06-10 | コーニンクレッカ フィリップス エヌ ヴェ | ロック構造を有するハウジング |
| RU2014123030A (ru) * | 2011-12-22 | 2016-02-20 | Ринат Ньюросайенс Корп. | Антагонистические антитела против человеческого рецептора гормона роста и способы их применения |
| WO2013123511A1 (en) * | 2012-02-16 | 2013-08-22 | New York University | Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics |
| WO2013192165A2 (en) | 2012-06-20 | 2013-12-27 | University Of Kansas | Compounds and methods for activating the apoptotic arm of the unfolded protein response |
| KR20150124962A (ko) | 2013-02-12 | 2015-11-06 | 유니버시티 오브 써던 캘리포니아 | 화학 독성 및 연령 관련 질병으로부터 보호하기 위한 방법 및 규정식 |
-
2016
- 2016-02-12 BR BR112017017182A patent/BR112017017182A2/pt not_active IP Right Cessation
- 2016-02-12 US US14/913,130 patent/US10246446B2/en active Active
- 2016-02-12 AU AU2016219173A patent/AU2016219173B2/en not_active Ceased
- 2016-02-12 ES ES16749947T patent/ES2871551T3/es active Active
- 2016-02-12 JP JP2017541934A patent/JP6930916B2/ja active Active
- 2016-02-12 KR KR1020177024899A patent/KR20180016333A/ko not_active Ceased
- 2016-02-12 WO PCT/US2016/017717 patent/WO2016130901A2/en not_active Ceased
- 2016-02-12 MX MX2017010306A patent/MX383010B/es unknown
- 2016-02-12 NZ NZ734252A patent/NZ734252A/en not_active IP Right Cessation
- 2016-02-12 CN CN201680010133.4A patent/CN107438605B/zh active Active
- 2016-02-12 EP EP16749947.4A patent/EP3256465B1/en active Active
- 2016-02-12 RU RU2017129335A patent/RU2726254C2/ru active
- 2016-02-12 CA CA2976219A patent/CA2976219C/en active Active
-
2017
- 2017-08-10 IL IL253943A patent/IL253943A0/en unknown
-
2019
- 2019-03-27 US US16/366,662 patent/US20190276445A1/en not_active Abandoned
-
2021
- 2021-02-08 JP JP2021018032A patent/JP2021075553A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190276445A1 (en) | 2019-09-12 |
| EP3256465A2 (en) | 2017-12-20 |
| CN107438605A (zh) | 2017-12-05 |
| MX2017010306A (es) | 2018-03-15 |
| US20170342063A1 (en) | 2017-11-30 |
| BR112017017182A2 (pt) | 2018-04-03 |
| EP3256465B1 (en) | 2021-04-07 |
| CN107438605B (zh) | 2021-03-19 |
| RU2726254C2 (ru) | 2020-07-10 |
| AU2016219173A1 (en) | 2017-08-17 |
| RU2017129335A3 (enExample) | 2019-08-07 |
| CA2976219A1 (en) | 2016-08-18 |
| JP2018506534A (ja) | 2018-03-08 |
| JP2021075553A (ja) | 2021-05-20 |
| EP3256465A4 (en) | 2018-10-31 |
| CA2976219C (en) | 2021-05-04 |
| WO2016130901A2 (en) | 2016-08-18 |
| WO2016130901A3 (en) | 2016-10-20 |
| ES2871551T3 (es) | 2021-10-29 |
| RU2017129335A (ru) | 2019-03-12 |
| KR20180016333A (ko) | 2018-02-14 |
| AU2016219173B2 (en) | 2020-02-20 |
| JP6930916B2 (ja) | 2021-09-01 |
| US10246446B2 (en) | 2019-04-02 |
| IL253943A0 (en) | 2017-10-31 |
| MX383010B (es) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| PH12014502449A1 (en) | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | |
| MX2016013243A (es) | Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4. | |
| MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
| PH12016501809A1 (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
| EP4424326A3 (en) | Modified nk-92 cells for treating cancer | |
| UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
| MX2017007321A (es) | Terapias de combinacion. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| MX386595B (es) | Métodos para el tratamiento del sobrepeso o la obesidad. | |
| TW201613633A (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
| EA201390194A1 (ru) | Улучшенный рекомбинантный фолликул-стимулирующий гормон человека | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| MX2015012322A (es) | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| WO2012156968A3 (en) | Use of mesenchymal stem cells for the improvement of affective and cognitive function | |
| MY201535A (en) | Therapeutic compounds | |
| GB2554591A (en) | Clinical support system and method | |
| WO2013106766A3 (en) | THERAPEUTIC INDICATIONS OF miR-1291 | |
| NZ734252A (en) | Blockers of the growth hormone receptor in disease prevention and treatment | |
| NZ719745A (en) | Soluble fc gamma receptor for treatment of autoimmune bullous diseases | |
| BR112014029302A2 (pt) | método de redução de peso | |
| MX2018000947A (es) | Marcadores geneticos asociados con la respuesta a los antagonistas del receptor crth2. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 FEB 2022 BY COMPUTER PACKAGES INC Effective date: 20210119 |
|
| LAPS | Patent lapsed |